Diversity in all clinical research—including rare disease research—is currently under scrutiny, partly because of disparities experienced with COVID-19. Rightly so, as data show that 86 percent of genomics studies to date have involved people of European ancestry, which has limited the potential benefits of genomic research for many populations. Rebecca Sutphen, Co-Founder and Chief Medical Officer of InformedDNA, and Board-Certified Genetic Counselor Karmen Trzupek analyze strategies to increase diversity in rare genetic disease trials.
Elon Musk’s Neuralink was beaten to the clinic by a rival brain-computer interface company. Synchron enrolled the first patient in the COMMAND study that will assess the New York-based company’s implant in individuals with severe paralysis.
For years, researchers have been moving towards decentralized clinical trials (DCTs), and in a matter of months, COVID-19 changed the trajectory. Clinical operations teams and investigator sites around the world rose to the challenge and worked quickly to deploy new tactics to serve their study participants. The resulting reward is that DCTs, which can be leveraged smartly to reduce participant burden and improve recruitment and retention, are now becoming more widely adopted in design considerations. But rewards bring about new risks and challenges, and DCTs create new concerns for monitoring participant safety. Dario Lirio – Senior Director, LifeSphere Clinical at ArisGlobal – analyzes the risks and rewards of DCTs.
If you flip through history, you’ll realize that our fundamental healthcare needs haven’t changed since the year 1885. We still seek rest when we’re ill, feel pain when we overexert ourselves, and need guidance from experts on our health and wellness. But the tools we have to meet these perennial needs have shifted dramatically since the 19th century, and especially over the past decade, wherein technology has advanced faster than even the greatest Sci-Fi film producers imagined, according to Greater Than One Chief Technology Officer Ken Winell.
Klick Health debuted The Mother of All Reviews, an emotional new video paying tribute to working moms in advance of Mother’s Day, and acknowledging the extra load they have shouldered throughout the pandemic. The video was produced in support of nonprofit Path Forward to help empower moms to restart their careers.
A recent CVS Health/Morning Consult survey of Americans age 18+ found that mental health concerns are continuing to rise among individuals of all backgrounds, especially Black, age 65+, young adult, and LGBTQIA+ respondents.
Elon Musk struck a deal to buy Twitter for $44 billion. Although a somewhat unconventional character, sleeping at the Tesla headquarters and eschewing wealthy materialism, make no mistake that Musk’s successful track record in business shows how significant Twitter may become under his leadership. While no one knows for sure what will be, Casey Ross – Social Media Strategy Director at FCB Health New York – looks at some of the issues Musk has publicly called out, and their potential implications for advertisers.
PharmaLive talked to Gerald Martinetz at Mindbreeze regarding how data is transforming R&D in the metaverse.
This paper explains the challenges patients face in traditional trial settings as well as how Aparito overcomes these challenges; how remote video is able to capture real-world evidence (RWE) while improving the patient experience; and how Aparito provides more meaningful patient data while protecting patient privacy.
Some rare blood disorders are a life-threatening emergency that require urgent action, but for some healthcare professionals (HCPs) it’s hard to recognize and treat a disease you rarely see or experience. McCann Health New Jersey, an IPG Health company, helped develop, design and support the launch of “FROM VERY RARE TO VERY REAL.” The virtual reality (VR) experience helps HCPs look beyond data and diagnostic algorithms, and instead actually feel like they are at the center of a real emergency.